BioLife Solutions vs Lantheus: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

BioLife Solutions Inc (BLFS)

Q3 202622 Jul – 5 Oct 2026

▲2▼2

Repligen's $1.5B buyout locks BLFS to deal terms, not its own news

Repligen agrees to buy BioLife for $1.5 billion Repligen will pay $31 a share — $11.25 cash plus Repligen stock — a 24% premium to BioLife's recent average price. That buyout price now acts like a magnet for the stock: it trades near the deal value, and shareholders get cash plus Repligen shares when it closes.
The acquisition is the single force now setting BLFS's price.
Q2 beat shows the underlying business was healthy BioLife earned $0.04 a share versus an expected small loss, with revenue of $28.5 million, up about 21% from a year earlier and above forecasts — its fourth straight beat. Strong results support the deal price and make the buyer's case easier.
Shows the company's own performance still matters as a backstop to the deal.
Law firm probes whether the sale price is fair Investor-rights firm Halper Sadeh is investigating whether BioLife's board got shareholders a fair deal in the Repligen sale. Such reviews are common and often lead nowhere, but they can delay closing or pressure the buyer to raise its offer.
A real counterweight that could change deal terms or timing.
Removed from the S&P SmallCap 600 index BioLife is being dropped from the S&P SmallCap 600 and replaced by Freshworks, because it is being acquired. Index funds that tracked it must sell, but with the buyout nearly done, this mostly reflects the deal closing rather than new weakness.
Explains the forced selling around the deal's completion.

August 202622 Jul – 5 Oct 2026

▲2▼2

Repligen's $1.5B buyout locks BLFS to deal terms, not its own news

Repligen agrees to buy BioLife for $1.5 billion Repligen will pay $31 a share — $11.25 cash plus Repligen stock — a 24% premium to BioLife's recent average price. That buyout price now acts like a magnet for the stock: it trades near the deal value, and shareholders get cash plus Repligen shares when it closes.
The acquisition is the single force now setting BLFS's price.
Q2 beat shows the underlying business was healthy BioLife earned $0.04 a share versus an expected small loss, with revenue of $28.5 million, up about 21% from a year earlier and above forecasts — its fourth straight beat. Strong results support the deal price and make the buyer's case easier.
Shows the company's own performance still matters as a backstop to the deal.
Law firm probes whether the sale price is fair Investor-rights firm Halper Sadeh is investigating whether BioLife's board got shareholders a fair deal in the Repligen sale. Such reviews are common and often lead nowhere, but they can delay closing or pressure the buyer to raise its offer.
A real counterweight that could change deal terms or timing.
Removed from the S&P SmallCap 600 index BioLife is being dropped from the S&P SmallCap 600 and replaced by Freshworks, because it is being acquired. Index funds that tracked it must sell, but with the buyout nearly done, this mostly reflects the deal closing rather than new weakness.
Explains the forced selling around the deal's completion.

Latest22 Jul – 5 Oct 2026

▲2▼2

Repligen's $1.5B buyout locks BLFS to deal terms, not its own news

Repligen agrees to buy BioLife for $1.5 billion Repligen will pay $31 a share — $11.25 cash plus Repligen stock — a 24% premium to BioLife's recent average price. That buyout price now acts like a magnet for the stock: it trades near the deal value, and shareholders get cash plus Repligen shares when it closes.
The acquisition is the single force now setting BLFS's price.
Q2 beat shows the underlying business was healthy BioLife earned $0.04 a share versus an expected small loss, with revenue of $28.5 million, up about 21% from a year earlier and above forecasts — its fourth straight beat. Strong results support the deal price and make the buyer's case easier.
Shows the company's own performance still matters as a backstop to the deal.
Law firm probes whether the sale price is fair Investor-rights firm Halper Sadeh is investigating whether BioLife's board got shareholders a fair deal in the Repligen sale. Such reviews are common and often lead nowhere, but they can delay closing or pressure the buyer to raise its offer.
A real counterweight that could change deal terms or timing.
Removed from the S&P SmallCap 600 index BioLife is being dropped from the S&P SmallCap 600 and replaced by Freshworks, because it is being acquired. Index funds that tracked it must sell, but with the buyout nearly done, this mostly reflects the deal closing rather than new weakness.
Explains the forced selling around the deal's completion.

Lantheus Holdings Inc (LNTH)

Q3 202626 Jun – 14 Aug 2026

▲2▼1

Curium's $8B buyout and new FDA approval reshape Lantheus

Curium agrees to acquire Lantheus for up to $8 billion Curium will pay $102.50 per share in cash plus up to $12 more if sales targets are met, a 14.9% premium. This puts a firm floor under the stock and is the main reason it trades near the offer price.
The buyout is the single biggest force driving LNTH's price and future value.
FDA approves Tauklarify for tau PET imaging The FDA approved Tauklarify, a new imaging agent for Alzheimer's tau pathology. This adds a new product to Lantheus's portfolio and could support the contingent value rights tied to future sales.
A new FDA approval is a fresh positive catalyst that can affect the buyout's contingent payments.
FDA rejects LNTH-2501 due to third-party facility issues The FDA issued a Complete Response Letter for LNTH-2501, a PET diagnostic for neuroendocrine tumors, because of unresolved manufacturing issues at a partner's facility. This delays a potential product but does not question the drug's data.
This is a fresh regulatory setback that could weigh on sentiment and future growth prospects.

July 202626 Jun – 14 Aug 2026

▲2▼1

Curium's $8B buyout and new FDA approval reshape Lantheus

Curium agrees to acquire Lantheus for up to $8 billion Curium will pay $102.50 per share in cash plus up to $12 more if sales targets are met, a 14.9% premium. This puts a firm floor under the stock and is the main reason it trades near the offer price.
The buyout is the single biggest force driving LNTH's price and future value.
FDA approves Tauklarify for tau PET imaging The FDA approved Tauklarify, a new imaging agent for Alzheimer's tau pathology. This adds a new product to Lantheus's portfolio and could support the contingent value rights tied to future sales.
A new FDA approval is a fresh positive catalyst that can affect the buyout's contingent payments.
FDA rejects LNTH-2501 due to third-party facility issues The FDA issued a Complete Response Letter for LNTH-2501, a PET diagnostic for neuroendocrine tumors, because of unresolved manufacturing issues at a partner's facility. This delays a potential product but does not question the drug's data.
This is a fresh regulatory setback that could weigh on sentiment and future growth prospects.

Latest26 Jun – 14 Aug 2026

▲2▼1

Curium's $8B buyout and new FDA approval reshape Lantheus

Curium agrees to acquire Lantheus for up to $8 billion Curium will pay $102.50 per share in cash plus up to $12 more if sales targets are met, a 14.9% premium. This puts a firm floor under the stock and is the main reason it trades near the offer price.
The buyout is the single biggest force driving LNTH's price and future value.
FDA approves Tauklarify for tau PET imaging The FDA approved Tauklarify, a new imaging agent for Alzheimer's tau pathology. This adds a new product to Lantheus's portfolio and could support the contingent value rights tied to future sales.
A new FDA approval is a fresh positive catalyst that can affect the buyout's contingent payments.
FDA rejects LNTH-2501 due to third-party facility issues The FDA issued a Complete Response Letter for LNTH-2501, a PET diagnostic for neuroendocrine tumors, because of unresolved manufacturing issues at a partner's facility. This delays a potential product but does not question the drug's data.
This is a fresh regulatory setback that could weigh on sentiment and future growth prospects.